Clinical Trials Logo

Histiocytoma, Malignant Fibrous clinical trials

View clinical trials related to Histiocytoma, Malignant Fibrous.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04099277 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study of LY3435151 in Participants With Solid Tumors

Start date: October 28, 2019
Phase: Phase 1
Study type: Interventional

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

NCT ID: NCT03670069 Terminated - Clinical trials for Metastatic Soft Tissue Sarcoma

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Start date: September 30, 2019
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02601209 Terminated - Myxofibrosarcoma Clinical Trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Start date: November 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01418001 Terminated - Sarcoma Clinical Trials

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Start date: August 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see the effects, good and/or bad, of the drug combination of gemcitabine, docetaxel and pazopanib on sarcoma. This is a phase Ib-phase II clinical trial. The goal of a phase Ib part of the clinical trial is to confirm a dose of the drugs that is safe. The investigators determine this by closely checking for side effects that the patient may experience.